Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures

Amira Mohamed, Marie Pierre Blanchard, Manuela Albertelli, Federica Barbieri, Thierry Brue, Patricia Niccoli, Jean Robert Delpero, Genevieve Monges, Stephane Garcia, Diego Ferone, Tullio Florio, Alain Enjalbert, Vincent Moutardier, Agnes Schonbrunn, Corinne Gerard, Anne Barlier, Alexandru Saveanu

Research output: Contribution to journalArticlepeer-review


Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) raise difficult therapeutic problems despite the emergence of targeted therapies. Somatostatin analogs (SSA) remain pivotal therapeutic drugs. However, the tachyphylaxis and the limited antitumoral effects observed with the classical somatostatin 2 (sst2) agonists (octreotide and lanreotide) led to the development of new SSA, such as the pan sst receptor agonist pasireotide. Our aim was to compare the effects of pasireotide and octreotide on cell survival, chromogranin A (CgA) secretion, and sst2 phosphorylation/trafficking in pancreatic NET (pNET) primary cells from 15 tumors. We established and characterized the primary cultures of human pancreatic tumors (pNETs) as powerful preclinical models for understanding the biological effects of SSA. At clinically relevant concentrations (1-10 nM), pasireotide was at least as efficient as octreotide in inhibiting CgA secretion and cell viability through caspase-dependent apoptosis during short treatments, irrespective of the expression levels of the different sst receptors or the WHO grade of the parental tumor. Interestingly, unlike octreotide, which induces a rapid and persistent partial internalization of sst2 associated with its phosphorylation on Ser341/343, pasireotide did not phosphorylate sst2 and induced a rapid and transient internalization of the receptor followed by a persistent recycling at the cell surface. These results provide the first evidence, to our knowledge, of striking differences in the dynamics of sst2 trafficking in pNET cells treated with the two SSAs, but with similar efficiency in the control of CgA secretion and cell viability.

Original languageEnglish
Pages (from-to)691-704
Number of pages14
JournalEndocrine-Related Cancer
Issue number5
Publication statusPublished - Oct 1 2014


  • Human pancreatic neuroendocrine tumors
  • Octreotide
  • Pasireotide
  • Primary culture
  • Receptor trafficking
  • Somatostatin receptors

ASJC Scopus subject areas

  • Endocrinology
  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)


Dive into the research topics of 'Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures'. Together they form a unique fingerprint.

Cite this